With the acquisition of Medidata and its clinical and commercial solutions, Dassault Systèmes will aim to reinforce its position as a science-based company by providing the Life Sciences industry with an integrated business experience platform for an end-to-end approach to research and discovery, development, clinical testing, manufacturing and commercialisation of new therapies and health technologies.
Tarek Sheif, co-founder, chairman and CEO, Medidata, said: “Our mission to get the right treatment, to the right patient, at the right time has fueled our 20-year journey of innovation and commitment to the life sciences industry. We share common vision, values and passion with Dassault Systèmes, and our combined talents will empower the life sciences industry with an end-to-end business platform.”
Since unveiling its purpose of harmonising product, nature and life in 2012, Dassault Systèmes has been steadily applying its knowledge and know-how for transforming the product sphere, to collaborative, multidisciplinary innovation in the biosphere.
Bernard Charlès, vice chairman and CEO, Dassault Systèmes said: “This marks a significant milestone for the Life Sciences industry and the value of the virtual world to address the complexity of developing personalised medicine and patient-centric experiences. Multidiscipline scientific innovation and industrial performance call for a platform approach connecting the dots between people, ideas and data. Medidata’s leading position in clinical trials complements our life sciences solutions on the 3DExperience collaborative platform. Medidata’s recent expansion into real world evidence and analytics coupled with the power of modelling and simulation demonstrates how the virtual world will catalyse the next generation of patient-inclusive therapeutics. We are now well positioned to be the enabler of the Life Sciences industry transformation, illustrating our company’s purpose of harmonising product, nature and life.”
Completion of the acquisition is expected during the last quarter of 2019 and is subject to certain regulatory approvals, approval by the majority of Medidata’s shareholders and other customary closing conditions.